Published in Virol J on December 21, 2009
Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A (2010) 1.42
Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. PLoS One (2011) 0.94
Therapeutic antibodies and infectious diseases, Tours, France, November 20-22, 2012. MAbs (2013) 0.93
Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS One (2011) 0.93
Mining human antibody repertoires. MAbs (2010) 0.92
Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody. J Virol (2015) 0.85
Influenza B-cells protective epitope characterization: a passkey for the rational design of new broad-range anti-influenza vaccines. Viruses (2012) 0.84
The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency. PLoS One (2014) 0.82
A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells. PLoS One (2015) 0.79
Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice. Antiviral Res (2016) 0.75
Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma. MAbs (2014) 0.75
Evolution and ecology of influenza A viruses. Microbiol Rev (1992) 39.99
Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell (1985) 6.44
Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods (1985) 6.11
Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol (1988) 5.31
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med (1999) 4.82
Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology (1991) 3.83
Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol (1991) 3.29
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine (2007) 2.76
Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine (2004) 2.72
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol (2004) 2.59
Structure of influenza virus haemagglutinin complexed with a neutralizing antibody. Nature (1995) 2.55
Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis (2007) 2.36
Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology (1981) 2.26
The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J Virol (2005) 2.23
Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine (2003) 2.00
Conservation of the influenza virus membrane protein (M1) amino acid sequence and an open reading frame of RNA segment 7 encoding a second protein (M2) in H1N1 and H3N2 strains. Virology (1981) 1.94
Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol (1989) 1.85
The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus. J Cell Biol (1996) 1.83
Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine (1995) 1.83
Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol (1990) 1.82
Regulation of pH by the M2 protein of influenza A viruses. Virus Res (1992) 1.63
Seasonal influenza vaccines. Curr Top Microbiol Immunol (2009) 1.63
An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem (2008) 1.51
CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine (2008) 1.38
N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication. FEMS Immunol Med Microbiol (2003) 1.35
Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine (2006) 1.32
Viral ion channels: structure and function. Biochim Biophys Acta (2002) 1.31
Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine (2009) 1.30
Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res (2008) 1.30
Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles. J Immunol Methods (2003) 1.27
Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett (2004) 1.26
Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A (2008) 1.14
Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology (2008) 1.13
A haemagglutinin (HA1)-specific FAb neutralizes influenza A virus by inhibiting fusion activity. J Gen Virol (2001) 1.06
Single, antigen-specific B cells used to generate Fab fragments using CD40-mediated amplification or direct PCR cloning. Biotechniques (1995) 1.03
High and low efficiency neutralization epitopes on the haemagglutinin of type A influenza virus. J Gen Virol (1997) 0.93
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol (2005) 3.14
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (2008) 2.77
Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science (2007) 2.67
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol (2004) 2.59
Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 2.54
Brain anatomy and sensorimotor gating in Asperger's syndrome. Brain (2002) 2.26
The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol (2004) 2.11
A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One (2008) 2.07
GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med (2008) 1.99
TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol (2007) 1.95
The coming of age of virus-like particle vaccines. Biol Chem (2008) 1.85
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol (2006) 1.84
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol (2005) 1.84
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol (2004) 1.74
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens (2007) 1.68
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity (2005) 1.63
Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol (2006) 1.59
CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci U S A (2009) 1.56
Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res (2010) 1.52
VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest (2006) 1.51
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 1.48
Slit2 involvement in glioma cell migration is mediated by Robo1 receptor. J Neurooncol (2007) 1.41
Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol (2002) 1.39
A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia (2004) 1.38
Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol (2011) 1.37
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity (2008) 1.34
Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A (2011) 1.33
Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol (2010) 1.32
Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol (2008) 1.30
Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation (2003) 1.29
In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry (2006) 1.29
Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol (2003) 1.26
The COMT val158met polymorphism and brain morphometry in healthy young adults. Neurosci Lett (2006) 1.25
Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A (2005) 1.21
How adeno-associated virus Rep78 protein arrests cells completely in S phase. Proc Natl Acad Sci U S A (2005) 1.15
Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A (2008) 1.14
A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol (2007) 1.13
Rapid response of marginal zone B cells to viral particles. J Immunol (2004) 1.13
Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol (2007) 1.12
Versatile virus-like particle carrier for epitope based vaccines. PLoS One (2010) 1.12
Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol (2010) 1.11
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol (2006) 1.11
Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs (2007) 1.11
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol (2002) 1.10
Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol (2012) 1.09
Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol (2003) 1.09
Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol (2012) 1.09
Asperger syndrome: a proton magnetic resonance spectroscopy study of brain. Arch Gen Psychiatry (2002) 1.09
A functional magnetic resonance imaging study of inhibitory control in obsessive-compulsive disorder. Psychiatry Res (2009) 1.08
Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol (2002) 1.07
Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol (2008) 1.07
Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. Am J Psychiatry (2006) 1.06
The effect of pre-mutation of X chromosome CGG trinucleotide repeats on brain anatomy. Brain (2004) 1.06
Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 1.06
Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol (2009) 1.05
Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine (2010) 1.05
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother (2010) 1.04
Dendrimers Based on [1,3,5]-Triazines. J Polym Sci A Polym Chem (2006) 1.04
Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med (2005) 1.04
Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med (2007) 1.03
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci (2011) 1.03
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J (2010) 1.03